The stock has a market cap of $9.39 billion and a P/E ratio of 34.16. Approximately 6,068,056 shares were traded during trading, an increase of 6% from the previous session’s volume of 5,707,351 shares.The stock last traded at $23.43 and had previously closed at $23.45. The firm’s 50-day moving average is $30.58 and its 200-day moving average is $32.39.
Advertisement
Canaccord Genuity reiterated their buy rating on shares of Digital Realty Trust (NYSE:DLR) in a report released on Thursday morning, Analyst Ratings.Net reports. Biomed Realty Trust has a 52 week low of $17.94 and a 52 week high of $25.11. The Company’s services include implementation services, remote hands services, data center infrastructure management (DCIM), client services and digital realty partner network. Stifel Nicolaus boosted their price objective on shares of Digital Realty Trust from $73.00 to $76.00 and gave the stock a buy rating in a research report on Wednesday, July 15th. The consensus analyst estimates according to First Call for the next quarter is 0.37. WTI crude oil spiked 3.4% to $49.43/bbl, briefly topping $50 for the first time since July, as Russia’s military involvement in Syria brought a geopolitcal risk premium into the market. The ex-dividend date is Monday, September 28th. The shares were sold at an average price of $29.03, for a total value of $29,030.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
The company’s shares have been trading at a discount, affected by volatile earnings and a lower-quality portfolio than its closest peer Alexandria Real Estate Equities Inc, BMO Capital Market analysts said in a note in September.
Digital Realty Trust, Inc.is a real estate investment trust (NYSE:DLR) that owns, acquires, develops and manages technology-related real estate. The Company’s tenants chiefly contain biotechnology and pharmaceutical companies, government agencies scientific research associations and other entities associated with the life science business.
Advertisement
“Demand for high-quality, institutional real estate to support the unprecedented growth of the life science industry is at historic levels as demand is outpacing supply in all of our core innovation districts”, Alan D. Gold, the chairman, president, and CEO of BioMed Realty, said in the press release. The healthcare REIT owns office properties catering to pharma and biotech companies.
